ClinicalTrials.gg
Enrolling by invitationNCT04669457Updated Jul 15, 2026

Pediatric Delirium

A Phase 4 interventional study of Intra-nasal Dexmedetomidine and Oral Midazolam in Pediatric Delirium, sponsored by University of Massachusetts, Worcester. Enrolling by invitation at 1 site in United States. Open to participants aged 3 Months to 9 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-15.

Sponsored by University of Massachusetts, Worcester · Phase 4, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
3 Months to 9 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 78 studies testing dexmedetomidine in Delirium — 14 open to participants now, 17 under way, 4 of them phase 3. Dexmedetomidine · Delirium.

Planned enrollment
49th of 78
60 · median 98
Started
2021
with 6 others
Phase 4
35 of 78
5 open now
Primary completion
2027-04
later than 9 of 16 live
Registered
54th of 78
by date

Among the 78 studies testing dexmedetomidine in Delirium, this one is the 49th largest by planned enrollment, is one of 7 that started in 2021, is one of 35 in phase 4, reaches primary completion later than 9 of the 16 other live ones, and was the 54th registered.

Delirium

935 studies on the registry are indexed under Delirium; 188 are open to participants now.

Browse Delirium studies →

Open to participants now

14 of the 78 studies testing dexmedetomidine in Delirium are open now, in 5 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 14 open studies →

About dexmedetomidine

Dexmedetomidine: first FDA approval 1999 (PRECEDEX), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 124 Delirium studies recruiting now, 96 (77%) set no upper age limit and 8 (6%) stop at 75 or younger; 8 take children under 18; 14 take healthy volunteers.

This study: 3 Months to 9 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 78 studies testing dexmedetomidine in Delirium, or all of them as a file.
02

Study summary

Preventing emergent delirium in pediatric ambulatory surgery through preoperative use of intra-nasal Dexmedetomidine and oral Midazolam.

Read the detailed description

Pediatric ambulatory patients will randomly be allocated to one of two groups. Group A which will receive Dexmedetomidine intra-nasally at a dose of 1 mcg/kg, approximately 15-25 minutes before entering the operating room or Group B which will receive Midazolam orally at a dose of 0.5 mg/kg (with a maximum dose of 20 mg), approximately 10-15 minutes before entering the operating room. Each subject will receive a Drug Acceptance scale, and Parental Separation Anxiety Scale (PSAS) mask Acceptance Scale to identify the differences in markers associated with pediatric delirium. End tidal Sevoflurane value during the surgery and at the time when patient leaves the OR, amount and dose of oral/rectal acetaminophen given in PACU, child's behavior for 48 hours post-operatively, and documented intake of oral analgesics will be collected to identify the reduced need for post-operative analgesia and behaviors associated with extended pediatric delirium.

03

Conditions studied

  • Pediatric Delirium

Browse trials for

04

Who can participate

Ages eligible
3 Months to 9 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects age 3 months to 9 years
  • Scheduled to undergo a myringotomy
  • (ASA) classification of I - II.

Exclusion criteria

Exclusion Criteria:

  • Subjects with unrepaired cardiac defects, including cyanotic congenital heart disease.
  • Anyone age 10 years or older.
  • Anyone with an of III or higher.
  • Non-English language speaker for whom short form consent is not available.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Care provider, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Intra-nasal Dexmedetomidine

    Subjects will receive Dexmedetomidine intra-nasally in the preoperative area. It will be administered at a dose of 1 mcg/kg, approximately 15-25 minutes before entering the operating room.

    Drug: Intra-nasal Dexmedetomidine

  • Active comparator
    Oral Midazolam

    Subjects will receive Midazolam orally in the preoperative area. It will be administered at a dose of 0.5 mg/kg (with a maximum dose of 20 mg), approximately 10-15 minutes before entering the operating room.

    Drug: Oral Midazolam

Interventions

  • DrugDexmedetomidineStudies of DexmedetomidineDexmedetomidine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Subjects will receive Dexmedetomidine intra-nasally in the preoperative area. It will be administered at a dose of 1 mcg/kg, approximately 15-25 minutes before entering the operating room.

    Also known as: Precedex

  • DrugMidazolamStudies of MidazolamMidazolam pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Subjects will receive Midazolam orally in the preoperative area. It will be administered at a dose of 0.5 mg/kg (with a maximum dose of 20 mg), approximately 10-15 minutes before entering the operating room.

    Also known as: Midazolam

06

What researchers measure

Primary outcomes

  1. Time to onset of pediatric delirium

    Time from when the patient is woken from anesthesia to the onset of delirium.

    Time frame: Zero minutes to 48 hours

  2. Time to offset of pediatric delirium

    Time from onset of delirium to the offset of delirium.

    Time frame: Zero minutes to 48 hours

  3. Duration of pediatric delirium

    Total time patient experiences delirium

    Time frame: Zero minutes to 48 hours

Secondary outcomes

  1. Drug Acceptance

    The willingness of the subject to take the drug was assessed in the pre-operative area

    Time frame: 10-25 minutes prior to surgery

  2. Parental Separation Anxiety Scale (PSAS)

    Anxiety score was determined when the child was separated from the parents according to four levels.

    Time frame: 0-48 hours

  3. Mask Acceptance Scale

    The child's acceptance of the mask by the anesthesiologist was rated as follows.

    Time frame: 1-10 minutes prior to surgery

  4. End tidal Sevoflurane value

    During the surgery and at the time when patient leaves the OR End tidal Sevoflurane value will be documented.

    Time frame: 0-12 hours

  5. Rescue analgesia in PACU

    The amount and dose of oral/rectal acetaminophen given in PACU was recorded.

    Time frame: 0-6 hours post surgery

  6. Home Behavior Analysis

    The child's parents were given a diary to document their behavior for 48 hours post-operatively at home.

    Time frame: 12-48 hours

  7. Oral analgesic use

    Document intake of oral analgesics like acetaminophen or ibuprofen

    Time frame: Two days post-operative

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — Data will be shared via publication as group data.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2021 (actual). Primary completion is estimated for Apr 2027, 71 months after the start.

Of 40 non-industry phase 4 interventional studies under Delirium, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 62. This study's planned 71 months is above that.

Counting every sponsor, half of 40 studies reached it within 44 months; a quarter within 25 and three quarters within 62.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 9, 2020
First posted
Dec 16, 2020
StartActual
Apr 27, 2021
Primary completionEst.
Apr 5, 2027
CompletionEst.
Apr 5, 2027
Last update
Jul 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04669457
Responsible party
R. Ian Richmond (Assistant Professor, Director of Clinical Operations, Dept of Anesthesiology and Perioperative Medicine, University of Massachusetts, Worcester) — Principal investigator
First posted
Dec 16, 2020
Start date
Apr 27, 2021
Primary completion
Apr 5, 2027 (estimated)
Completion
Apr 5, 2027 (estimated)
Last update
Jul 15, 2026

Study contacts

R. Ian Richmond, MD
principal investigator · University of Massachusetts, Worcester

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexmedetomidine

Start the discussion